Sentences with phrase «with metastatic lung cancer»

Among patients with metastatic lung cancer, comorbidity had less impact on survival.

In January, Jeffrey Engelman, a thoracic oncologist at Massachusetts General Hospital in Boston, and his colleagues detailed the case of a 52 - year - old woman with metastatic lung cancer in The New England Journal of Medicine.

«People don't talk about «curing» patients with metastatic lung cancer.

Geoff Oxnard, an assistant professor of medicine at Dana - Farber Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.»

Dogs with metastatic lung cancers generally have several tumors in the lungs, not just a single growth.

Not exact matches

It has shown promise in metastatic melanoma, renal, and lung cancers — the last of which represents a huge opportunity for pharmaceutical companies (160,000 Americans are expected to die from lung cancer this year, compared with 10,000 from melanoma).

I have recently been diagnosed with metastatic breast cancer which has metastasized to both my lungs and possibly one ovary.

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

The study has been tested in metastatic patients with different primary tumours such as breast, colon and lung cancer.

The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.

Progression - free survival in the trial escalated from 3.5 months to 9.7 months with the addition of radiation therapy delivered to all the metastatic sites of lung cancer as well as the primary disease site.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for patients with metastatic ALK positive lung cancer.»

When William Pao was a medical oncology fellow at Memorial Sloan Kettering Cancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy reCancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy recancer (NSCLC) was rote: Every patient received the same chemotherapy regimen.

Among lung cancer patients; suicide SMR was higher in males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), older patients (70 - 75 years; SMR = 12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR = 11.2), patients presenting with metastatic disease (SMR = 13.9) and in patients who refused to receive surgical treatment (SMR = 13).

The researchers prospectively collected blood and tissue samples from 161 patients with metastatic breast cancer, non-small-cell lung cancer (NSCLC), or castration - resistant prostate cancer.

Metastatic lung cancer developed in the proband's mother, and the radiographic appearance of the lung cancer was the same for both women, with bilateral ground - glass opacities and pulmonary nodules.

«This technology [stereotactic body radiation] has been used successfully in both primary and metastatic lung and liver cancers, notably for patients who could not otherwise undergo surgery, with local control rates in excess of 90 percent» says Gan.

The first experiment is to measure metastatic lung cancer in MMTV - PyMT transgenic mice crossed with the POSTN Knock out mice, and controls, with focus on the role of periostin in metastatic progression.

Equally lethal is metastatic lung cancer, with an approximate 85 % mortality within 5 years of diagnosis.

A Phase 2 Study of MM - 121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Immunotherapy using checkpoint inhibitors has changed the way we treat several aggressive cancers such as melanoma, non-small cell lung and head & neck cancers, among others, with durable responses achieved in the metastatic setting.

The FDA approved Opdivo ® (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) after prior therapy.

The FDA granted approval to atezolizumab (TECENTRIQ), and anti-PD-L1 checkpoint inhibitor, for patients with metastatic, chemotherapy - resistant non-small cell lung cancer (NSCLC).

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

Merck's anti-PD-1 drug pembrolizumab (MK - 3475) is currently being investigated in a large a phase I trial for patients with metastatic melanoma and lung cancer.

This drug will be used for patients with metastatic or advanced lung cancer who did not respond to previous treatments.

In March, the U.S. Food and Drug Administration approved nivolumab for patients with advanced (metastatic) squamous non-small cell lung cancer.

Melodie Beckham (left), here with her daughter, Laura, had metastatic lung cancer and chose to stop taking medical marijuana after it failed to relieve her symptoms.

This drug is indicated in combination with Cisplatin (a chemotherapeutic drug) for the first - line treatment of patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

Symptoms of primary and metastatic lung cancer are similar, although dogs with metastatic disease don't cough as much, according to the Merck Veterinary Manual.